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Genomics is advancing the understanding of neurodevelopmental conditions such as in-tellectual disability, autism spectrum disor-
der, and global developmental delay.1 Despite these 
promising advances, genomics has not yet reached the 
treatment and management of neurodevelopmental 
conditions to the same extent as it has certain other 
specialties, such as oncology.2 One response that may 
address this disparity are new pharmaceutical treat-
ments for genetic neurodevelopmental conditions. 
These treatments are now in development, with the aim 
to eliminate the underlying condition, rather than tar-
get discrete symptoms individually. Clinical research 
that advances to drug trials is a key step in the pathway 
from basic science to clinical care.  
Clinical research into genetic neurodevelopmental 
conditions has increased the number of families being 
offered opportunities to enroll their child in clinical 
drug trials. It is therefore a good time to consider par-
ents’ decision-making processes, along with the recruit-
ment and consent procedures with which parents must 
engage in order to enroll their child. Although we focus 
here mainly on parental decision-making for minors, 
much of what we discuss applies also to decision-mak-
ing for adult children. The capacity to make decisions is 
often impaired in individuals with neurodevelopmental 
conditions, and their parents often must make decisions 
on their behalf for their entire life.
Research consent processes commonly rely on writ-
ten study information.3 As clinical research increases in 
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its complexity and reach, so too does the complexity of 
information to be communicated to prospective partici-
pants or, for minors and for many adults with limited 
capacity for independent decision-making, their par-
ents. As a result, research enrollment materials are often 
extensive and exceed levels of general understanding.4 
One problematic assumption of this approach (i.e., the 
focus on providing information) is that offering infor-
mation fulfills the intent of the consent process.5 
There are fewer opportunities for children, includ-
ing those living with neurodevelopmental conditions, to 
participate in clinical research compared to opportuni-
ties for neurotypical adults. This is in part because past 
exploitation of children and those with neurodevelop-
mental conditions led to increased oversight and safe-
guards to protect these more vulnerable populations. 
Below, we discuss how a failure to appreciate the con-
text in which decisions about research opportunities are 
made for individuals with genetic neurodevelopmental 
conditions, including minors and adults with reduced 
decisional capacity, may lead to marginalization and 
even exclusion of these populations from research. This 
is a timely consideration due to an increasing focus on 
equity and inclusivity in research (and in society more 
generally). We advocate for the importance of ensur-
ing that those responsible for clinical research oversight 
and clinical investigators are aware of the considerations 
specific to people with these conditions.
Herein, we consider the importance of increas-
ing clinical research opportunities for individuals with 
neurodevelopmental conditions, ensuring that those 
overseeing such research are appropriately aware of the 
context-specific considerations and potential barriers 
for these populations. We also discuss the negative im-
plications of a narrow focus on information provision in 
the specific context of families of children who are not 
neurotypical (e.g., those living with genetic neurode-
velopmental conditions) and suggest potential ways to 
mitigate these implications. We argue that recruitment 
and consent processes should be optimized for families 
of children with neurodevelopmental conditions. 
We also introduce a further issue that parents may 
face: as new drug treatments aim to target the under-
lying mechanism of these conditions, parents may be 
concerned about the loss of positive aspects of their 
child’s condition (such as their child’s unique personal-
ity) along with the debilitating symptoms. This reflects 
a wider ethical issue: whether reversing neurodevelop-
Table 1. 
Challenges Raised by and Proposed Solutions for Enrolling Children in Clinical Trials 
for Genetic Neurodevelopmental Conditions
Challenges Proposed solutions
Investigators and IRBs may lack  Investigators and IRBs should strive to be aware of and sensitive to families’ 
appreciation of the contextual   circumstances.  
experience of disabilities. 
 
Informed consent processes tend to focus  Investigators and IRBs should reimagine the goals of informed consent to serve a 
narrowly on information provision.  range of functions.
 Investigators could use interactive consent platforms.
Parents and their children may have  Investigators could use narratives of adults with lived experiences of disability to 
differing perspectives about trial  increase parents’ awareness.
enrollment and treatment.  
 Investigators could use digital support tools to enhance shared decision-making.
Parents may have to reconcile themselves  Further context-specific social science and normative research should be  
to the possibility that novel treatments conducted, published, and critically discussed.  
may impact their child’s personal identity  
and authenticity. 
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mental conditions is justified in all cases. This broader 
issue is important, but here we will focus on the ethical 
issues that arise for parents as they consider whether to 
enroll their children in relevant trials.
We begin by describing neurodevelopmental condi-
tions and developments in treatments for these condi-
tions. We then critically review existing concerns over 
enrollment processes in research and suggest ways to 
address them (a summary is provided in the table). We 
focus on fragile X syndrome, which is the most com-
mon form of inherited intellectual disability. Among 
genetic conditions for neurodevelopmental conditions, 
the most treatment advances have been made for fragile 
X syndrome. We argue that enrolling children with ge-
netic neurodevelopmental conditions into clinical trials 
raises novel ethical challenges due to the curative nature 
of these treatments, which target underlying pathways. 
We recommend further exploration in this area to in-
form the development of approaches to enrolling chil-
dren into these drug trials that consider more dimen-
sions of the contexts in which the families make such 
decisions.
GENETIC NEURODEVELOPMENTAL CONDITIONS
Neurodevelopmental conditions are caused by brain impairments that present in childhood.6 
The conditions overlap clinically, with many manifest-
ing as cognitive deficits and behavioral challenges due 
to intellectual disability and autism. People with neu-
rodevelopmental conditions are a heterogeneous group 
that includes individuals who lack capacity for inde-
pendent decision-making throughout their lifespan. 
Therefore, as mentioned, parents often play a key role 
in making decisions on behalf of not only their minor 
but also their adult children with such conditions.7 
Some neurodevelopmental conditions are identi-
fied abruptly due to an infection, trauma, or congenital 
malformation, while others develop more subtly, with 
developmental delays becoming apparent as a child 
grows older. In these latter cases, the precise cause is of-
ten unknown, although most are likely associated with 
pathogenic (i.e., disease-causing) genetic variants that 
may have been inherited or have spontaneously arisen 
in the individual. 
Within genetics and medicine, there is a continu-
um of understanding about the genetic contribution 
to neurodevelopmental conditions across conditions.8 
At one extreme, genetic causes are largely unknown, as 
in the case with attention deficit hyperactivity disorder 
(ADHD). While ADHD does appear to run in families, 
only a small subset of the associated genes have been 
identified to date. 
At the center of the continuum are conditions such 
as autism spectrum disorder. Some genes associated 
with this condition have been identified, but many cases 
have no known genetic contribution, suggesting that 
the condition often results from an interplay of many 
genes.9 Two predominant models have emerged to ex-
plain the genetics of autism spectrum disorder. Some 
cases are caused by one or a handful of strong-to-mod-
erate disease-causing variants, whereas other cases are 
likely caused by many weak disease-causing variants, in 
combination with environmental factors.10
At the other end of the causal spectrum are con-
ditions for which variation in a specific gene has been 
identified as the cause. An example is fragile X syn-
drome, the most commonly inherited cause of intellec-
tual disability, associated with behavioral and learning 
challenges. As mentioned, we will focus on fragile X 
syndrome because of its frequency and the availability 
of clinical trials.11 However, the issues we explore are 
likely to be relevant to other genetic neurodevelopmen-
tal conditions for which pharmaceutical treatment may 
be available in the future. This includes conditions such 
as Angelman syndrome, 16p11.2 deletion or duplica-
tion syndrome, and many others that are increasingly 
As new drug treatments aim to target 
the underlying mechanism of genetic 
neurodevelopmental conditions,  
parents may be concerned about the 
loss of positive aspects of their child’s 
condition, such as their child’s unique 
personality.
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identified and diagnosed as a result of improvements in 
genomic testing capabilities.12 
As with many genetic neurodevelopmental con-
ditions, there is a wide spectrum of clinical features 
among individuals with fragile X syndrome. Behavioral 
symptoms include anxiety, aggression, attention defi-
cits, hyperactivity, and autism.13 Cognitive and social 
impairments occur in most males with fragile X syn-
drome, while these deficits are significantly milder in 
females with this condition. Individuals with fragile X 
syndrome often have distinct personality traits such as 
a cheerful disposition and sense of humor.14 Mothers 
of children with fragile X syndrome who are carriers of 
the condition have a higher incidence of social anxiety 
and depressive symptoms than is found in the general 
population.15 
Existing pharmaceutical treatments for fragile X 
syndrome target discrete symptoms such as inattention, 
hyperactivity, or aggressive behaviors. Genomics has 
advanced understanding of the underlying cause of sev-
eral neurodevelopmental conditions, in particular frag-
ile X syndrome, leading to a new generation of potential 
treatments and interventions that target the underlying 
molecular pathway of the condition.16 New, experimen-
tal treatments for fragile X syndrome (such as mGluR5 
negative allosteric modulators, or NAMs) aim to ad-
dress underlying brain dysfunction and provide global 
symptom reduction, including improvement of cogni-
tive and learning impairment.17 The goal of these treat-
ments is to provide what is essentially an irreversible 
cure for the condition. While treatments like NAMs are 
not yet available, clinical trials aiming to demonstrate 
their effectiveness (mostly phase II and some phase III) 
are underway.18 Additionally, it is hoped that the ad-
vances in fragile X syndrome drug development will 
inform advances in treatment for other genetic neuro-
developmental conditions.19
PEDIATRIC CLINICAL RESEARCH AND ENROLLMENT 
DECISIONS
Pediatric clinical research is essential to advances in treatment of neurodevelopmental conditions, as 
generalizing evidence from adults to pediatric patients 
is an inadequate approach. For example, children’s 
developing brains may react differently from those of 
fully developed adults.20 In the mid-twentieth century, 
efforts to enhance research regulation (and through 
this to protect children against exploitation in research) 
culminated in the development of guidelines such as 
the World Medical Association’s Declaration of Helsin-
ki and The Belmont Report in the United States.21 
International guidelines were key to establishing an 
essential discourse on pediatric clinical research. Yet a 
delicate balance exists between protecting children in 
research and ensuring that protections do not unneces-
sarily obstruct development of pediatric-specific drug 
safety and efficacy data. Efforts to increase pediatric-
specific data serve both scientific (improved knowl-
edge) and ethical (distributive justice) purposes.22 But 
a wider problem remains regarding the underrepresen-
tation of many groups (including children, people with 
disabilities, women, and people of color) in pharmaceu-
tical research. 
While there has been an increase in pediatric clini-
cal research in recent decades, a 2012 report showed 
that, overall, a discrepancy remains; there were 10 times 
more clinical trials for adults than for children.23 Of 
the pediatric trials that are initiated, 19% are discontin-
ued, often due to low recruitment and poor retention of 
participants.24 A more recent analysis of clinical trials 
concerning rare diseases reported that 12% of the trials 
focused on the pediatric population; within that study, a 
discontinuation rate of 30% was found in the pediatric 
trials.25 The comparatively smaller number of pediatric 
clinical trials among clinical trials in general is, in part, 
attributable to historical events in pediatric research, 
where children were exploited or harmed.26 
Mitigation attempts in response to this continuing 
underrepresentation include recent legislative advances 
such as the Best Pharmaceuticals for Children Act in the 
United States, which is accelerating the accumulation of 
pediatric-specific drugs.27 As new treatments for neu-
rodevelopmental conditions are developed, there is an 
expanding need for children to be enrolled in clinical 
drug trials to amass evidence on high-quality safety and 
dosage information. 
There are further considerations with respect to en-
rolling children with neurodevelopmental conditions 
into clinical drug trials. Families of children with these 
conditions have historically been underserved by and 
disenfranchised and often excluded from research op-
portunities.28 Recent evidence shows that parents want 
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their children to participate, although they may face 
barriers beyond those faced by families of neurotypi-
cal children.29 These barriers include challenges in de-
termining whether a child with a neurodevelopmental 
condition can contribute to decisions about enrollment 
and challenges for the parent in engaging with such de-
cisions while experiencing many other demands associ-
ated with caring for a child with a neurodevelopmental 
condition. Among families of children with neurodevel-
opmental conditions, those that report greater stress are 
less likely to join a clinical research registry.30 This is of 
particular relevance to families of children with fragile 
X syndrome, in which (as mentioned) female carrier 
status is associated with higher risks for social anxiety 
and depressive symptoms.31 
For any research involving children, regulations 
generally require parental permission and, if the child is 
capable, their affirmative agreement (discussed further 
below).32 These decisions can be difficult for parents, 
particularly as risks and benefits can be highly subjec-
tive. Institutional review boards (IRBs) and the research 
team have prominent roles in determining whether spe-
cific research involving children is acceptable. Freed-
man and coauthors introduce the related concept in 
loco parentis to describe scenarios whereby studies that 
may pose an unacceptable risk to children are evaluated 
by the research team and IRBs and filtered out early, 
prior to reaching the stage that requires parental per-
mission.33 
For a concept such as in loco parentis to function, in-
vestigators need to have a thorough working knowledge 
of the target population, and IRBs tasked with approv-
ing such research should be flexible and able to under-
stand families’ perspectives on their child’s participation 
in research. Sabatello and coauthors warn that IRBs may 
inadvertently be overly restrictive and unnecessarily 
exclude individuals with disabilities (including those 
with neurodevelopmental conditions) from participat-
ing in clinical research. In an attempt to mitigate such 
risks, they describe the importance of what they term 
“disability cultural competence” for those working with 
patients and families with disability who are enrolled or 
considering enrolling in clinical research.34 Such train-
ing, awareness, and sensitivity can positively contribute 
to enabling inclusivity in research. Investigators devel-
oping drugs for genetic neurodevelopmental conditions 
and IRB members approving protocols to test these 
drugs thus have a responsibility to ensure that they are 
knowledgeable about the circumstances of these families 
and how to best support them to make decisions about 
clinical trial enrollment. Cascio and colleagues recently 
conducted a literature review to highlight strategies that 
can be employed to ensure that research involving indi-
viduals with autism spectrum disorder can respect the 
needs of both the individual participant and the group 
to advance knowledge about the condition. They argue 
for a “person-orientated research ethics framework” 
that is flexible to meet the needs of individuals with 
the disorder.35 Such a framework could be used when 
designing and conducting research involving children 
with genetic neurodevelopmental conditions.
CURRENT ISSUES WITH CONSENT PROCESSES
The consent processes in medical research are in-creasingly recognized as problematic.36 The con-
cept of informed consent emphasizes participants’ un-
derstanding of key relevant information. However, it 
is challenging to determine how much information a 
potential participant needs to make an informed deci-
sion. Many participants fail to understand basic con-
cepts about the research in which they are enrolled.37 
As medical research has become increasingly sophis-
ticated, the length and complexity of information pro-
vided to participants during the consent process has in-
creased.38 Focusing too narrowly on information also 
potentially neglects other relevant aspects of research 
participation, such as ensuring that decisions reflect 
the values of the decision-maker. A possible solution 
to these challenges lies in adopting a more holistic 
approach to the goals of informed consent, one that 
reaches beyond simply informing participants. 
The challenge of information provision and the val-
ue of moving away from a conceptualization of consent 
that focuses too narrowly on providing information 
are particularly relevant to genetic neurodevelopmen-
tal conditions. Beyond the features common to clinical 
trial research for the wide range of health conditions 
(e.g., randomization, placebos, and the risk of side ef-
fects), trials for fragile X syndrome treatments may have 
the added complexity of targeting genetic pathways.39 It 
is widely documented that levels of genetic literacy are 
low across the public at large.40 This added layer of com-
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plexity that may need to be conveyed to families could 
further impede an informed consent process that relies 
too heavily on information provision. There are efforts 
underway in other disease contexts to reduce the com-
plexity of the informed consent process.41 However, 
assessing the effectiveness of these efforts has thus far 
been limited to studies of relatively well-educated adults 
making decisions about their own participation in re-
search.42 
One approach to the problem of the increasing 
complexity of information about trials is to critically 
consider the roles that information provision and un-
derstanding should play in consent processes. Beskow 
and colleagues, for example, suggest that understand-
ing is an “ethical aspiration” rather than a requirement 
for enrollment in research.43 In their recent empirical 
study, their participants (who were experts such as bio-
ethicists, geneticists, social scientists, and community/
patient representatives) were confronted with the reality 
that many adults would be excluded from research if re-
quired to reach a particular threshold of understanding 
about study information.44 Therefore, the expert par-
ticipants adjusted their opinions about what should be 
considered required understanding. 
Further, when information is provided during study 
enrollment, this communication generally consists of a 
unidirectional process of information provision. Adult 
learning theory and education research indicate that 
merely having information relayed to oneself is one of 
the most ineffective ways of learning.45 One response 
to this could be to reduce the emphasis on providing 
detailed information within the consent process and to 
increase efforts that focus on parents’ concerns and feel-
ings about the research. This is particularly pertinent 
to consider for enrollment in fragile X syndrome trials, 
given the added layer of complexity associated with the 
experimental treatments. 
Informed consent should also be conceptualized 
beyond the one-off interaction that occurs when an in-
vestigator provides study information to the potential 
participant or their proxy decision-maker and this per-
son agrees to or declines enrollment. Informed consent 
should instead be seen to serve a variety of functions, 
which occur across a range of interactions and time 
points. Dickert and colleagues describe many functions 
of consent, including alignment of participant values 
with their enrollment decisions, promotion of trust, and 
protection of the welfare of participants.46 These specif-
ic functions may be particularly relevant to trials involv-
ing children with neurodevelopmental conditions, and 
they relate closely to points raised earlier about why it is 
important for investigators and IRB members to appre-
ciate the contexts of these families and to develop dis-
ability cultural competencies. 
There are also practical tools that can be employed 
to reframe informed consent as a dynamic process be-
yond information provision in a one-off interaction. 
For example, interactive consent platforms and decision 
aids that promote values clarification can be developed 
and tested.47 These tools may have particular value in 
the context of enrolling children with neurodevelop-
mental conditions. Consider the reality of traditional 
consent interactions with families in which a child has 
fragile X syndrome. If the child is present, they may be 
disruptive and anxious, especially in an unfamiliar envi-
ronment, impacting parents’ ability to concentrate and 
absorb necessary information. This is coupled with the 
potential for the mother to have symptoms of anxiety 
as part of her carrier phenotype, which can make these 
types of decisions particularly challenging.
A particular consideration for informed consent in 
the context of genetic neurodevelopmental clinical tri-
als is whether parents, especially if not themselves diag-
nosed with the condition in question, appreciate what 
is in their specific child’s best interest. While there is no 
doubt that parents are likely to do what they think is in 
the best interest of their child, it may not be possible 
to determine what is in the child’s best interest without 
having the experience of being affected by the condi-
tion. Further, for diagnosed individuals who choose to 
actively participate in decisions about trial enrollment, 
and have the capacity to do so, there is the potential 
for choice discrepancies to arise between parents and 
children. In the context of treatment options for autism 
spectrum disorder, for example, Perry suggests that par-
ents may lack the intimate insight their child possesses 
through their lived experience with the condition.48 
A solution Perry provides for the possible disconnect 
between parents’ and children’s perspectives is to offer 
parents access to narratives from adults with autism 
spectrum disorder. Such narratives may be effective in 
contributing to parents’ understanding of the lived ex-
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perience of autism spectrum disorder and inform their 
decision-making about treatments, including enroll-
ment in clinical drug trials. We endorse this suggestion 
and encourage further investigation into its wider use 
across other neurodevelopmental conditions. 
Additionally, soliciting the potential research par-
ticipant’s preference can be useful and important. As we 
have discussed, there is a wide spectrum of symptom 
severity among individuals with genetic neurodevelop-
mental conditions. Even with a relatively well-described 
condition such as fragile X syndrome, individuals vary 
widely in cognitive functioning from mildly to severely 
affected. Digital support tools may provide an interac-
tive and accessible option for adolescents and adults 
with limited decisional capacity to participate in the 
consent processes, enhancing shared decision-making 
between affected individuals and their parents.49 These 
tools use interactive multimedia (audio, visual, and nar-
ration) with features such as an avatar that walks par-
ticipants through the consent process, sorting exercises 
to engage participants in the decision, and knowledge 
checks.
In summary, while families of children with neu-
rodevelopmental conditions may be at increased risk 
of experiencing the limitations of current informed 
consent processes, this could be somewhat mitigated 
by reducing consent processes’ focus on information 
provision and through the use of tools to support both 
parents and potential participants who are engaged in 
enrollment decisions. This will, in turn, promote other 
important components of trial participation, including 
alignment with participant values and trust in both the 
researchers and the IRB process.
NOVEL CHALLENGES FOR PARENTS 
Anecdotally, there is widespread support from the fragile X syndrome advocacy community for 
developing the novel treatments we have described 
above.50 To advance these efforts, engagement with pa-
tient and community stakeholders in identifying treat-
ment priorities is key to the drug development process 
and indeed is endorsed by the U.S. Food and Drug 
Administration’s Patient-Focused Drug Development 
initiative.51 
Despite this widespread support, parents of children 
with fragile X syndrome nevertheless have to reconcile 
their thoughts about which attributes of the syndrome 
they wish to see reduced in their child with their ideas 
about which others they may perceive to be authentic 
aspects of their child’s character or personal identity, 
of “who their child is,” and thus important to preserve. 
From research in a comparable context, we know that 
parents of children with Down syndrome have ex-
pressed concerns that a cure for Down syndrome could 
change their child’s personality.52 Like individuals with 
Down syndrome, those with fragile X syndrome often 
have cheerful, pleasant personalities.53
Further parallels could be drawn from discourse 
about the use of stimulants such as Ritalin (methyl-
phenidate) or Adderall (amphetamine/dextroamphet-
amine) in children living with ADHD. Hinshaw et al. 
raise concerns that the use of these drugs may threaten 
one’s authenticity or mask one’s “true self.”54 Empirical 
work by Singh, however, suggests that, from the child’s 
perspective, while psychotropic drugs do impact their 
behavior, concerns about threats to their authenticity 
were unfounded.55 
Nevertheless, there are two points of difference be-
tween pharmaceutical treatment for fragile X syndrome 
compared to for ADHD. First, drug interventions for 
ADHD target the behavioral symptoms of the condi-
tion, whereas the drugs in development for fragile X 
syndrome target the underlying cause (with a view to 
improving both behavioral and cognitive symptoms). 
Second, these fragile X syndrome drugs aim to provide 
what is essentially an irreversible cure for the condition, 
whereas drugs such as Ritalin temporarily target behav-
ioral symptoms with no or few long-term implications 
and the possibility to stop treatment at any time. There 
may be value in replicating empirical work, such as that 
done by Singh, with families of children with fragile 
X syndrome. A recent qualitative study by Boardman 
explored views about population screening programs 
for fragile X syndrome by interviewing affected fami-
lies, including two individuals diagnosed with the syn-
drome.56 While not the primary focus of the study, one 
theme incorporated concepts about identity. Boardman 
documented disparate views from parents of affected 
individuals about whether a distinction between a per-
son and their condition was possible in this context. 
Empirical data are scarce about parents’ perspec-
tives on the impact on the child’s personality of novel 
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medications to treat fragile X syndrome. A qualitative 
study by D’Amanda and colleagues with 34 parents of 
children with fragile X syndrome found that personal-
ity strengths such as happiness, kindness, and compas-
sion were perceived as the most positive aspects of their 
child’s condition.57 These investigators also found that 
the majority of parents were not concerned that these 
personality strengths could be affected by an experi-
mental drug treating the underlying condition. How-
ever, a small number of parents voiced some concerns 
about such drugs “removing the blindfold,” in that frag-
ile X syndrome allows their child to live a sheltered and 
relatively carefree life.58 These data indicate that further 
context-specific evidence may be warranted and that 
ongoing engagement with stakeholder communities, to 
better understand the priorities of parents and families, 
will continue to be key to successful treatment trials. In 
parallel, further normative exploration of concepts such 
as authenticity in the context of fragile X syndrome and 
other genetic neurodevelopmental conditions is impor-
tant to increase understanding of the implications of the 
availability of a pharmaceutical cure. 
CONCLUSION
With the increasing number of clinical trials that target genetic conditions with behavioral and 
cognitive impairments, more parents with children liv-
ing with these conditions will face difficult decisions 
about their willingness to enroll their children in these 
trials. There are limitations to current consent and re-
cruitment processes that impact these families. To help 
overcome these challenges and work toward solutions 
that promote inclusivity, engaging with people with 
genetic neurodevelopmental conditions and their par-
ents will be key (see the table). Furthermore, ensuring 
“disability cultural competence” among IRBs and regu-
lators overseeing clinical research may help to ensure 
these populations benefit from such research.59 Even if 
we reach a stage where these processes are optimized 
for all stakeholders, parents will still (with appropriate 
support) need to reflect on their own values and per-
ceptions about whether treatments targeting the un-
derlying mechanism of genetic neurodevelopmental 
conditions could impact their child’s personhood and 
on their level of comfort around that notion.s
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